ArticleAnnals of medicine2025
Vasoactive intestinal peptide reduces ocular hypertension by regulating tight junction of trabecular meshwork through Rab13/PKA signalling complex.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchlemm's canal and trabecular meshwork (TM) are conventional outflow pathway of aqueous humour, which play an important role in maintaining intraocular pressure (IOP) homeostasis. Our previous research has implied that vasoactive intestinal peptide (VIP) reduces high IOP by regulating the distribution of F-actin in the endothelial cells of Schlemm's canal. In this study, we investigated the mechanism by which VIP affects tight junction (TJ) of TM.
methodsBurning three episcleral veins in the eye of rats and pressure-stimulating human trabecular meshwork cells (HTMCs) were respectively employed to establish high IOP animal and cell models. The IOP of the rats was measured by TonoLab during the period of 1-2 min after isoflurane anaesthesia at 10:00 to 11:00 a.m. on the measurement day. The tissue density of TM was observed by haematoxylin-eosin staining. Western blotting, qRT-PCR, immunofluorescence and immunohistochemistry were utilized to assess the levels of ZO-1, Claudin-1, Rab13 and PKA in TM tissue or cells.
resultsThe expression of TJ-related proteins ZO-1 and Claudin-1 increased significantly in high IOP rat models and pressure-stimulated HTMCs. Furthermore, both VIP and the overexpression of Rab13 reduced the expression of TJ-related proteins ZO-1 and Claudin-1 in pressure-stimulated HTMCs. However, the knockdown of Rab13 reversed the effect of VIP on TJ
conclusionsVIP inhibited TJ of TM cells by regulating the Rab13-PKA signalling complex, leading to the reduction of ocular hypertension in rats. This study provides new sights for the treatment of ocular hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.